Publications by authors named "Mariela Dutra Gontijo Moura"
Article Synopsis
- The study examined the presence of Epstein-Barr virus type 1 (EBV-1) DNA in HIV patients with oral hairy leukoplakia (OHL) before and after various topical treatments.
- A total of 15 patients received different topical therapies, including podophyllin resin alone or in combination with acyclovir or penciclovir, with samples tested for EBV-1 DNA.
- Results showed clinical healing in all groups, but 73.3% still had EBV-1 detectable after treatment, and some patients experienced recurrences, highlighting a link between treatment type and virus persistence.
A new topical treatment protocol for oral hairy leukoplakia.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
November 2010
Objective: The aim of this study was to present a new topical treatment protocol for oral hairy leukoplakia (OHL), consisting of a 25% podophyllin resin with a 1% penciclovir cream (PP), and to compare this topical treatment protocol's efficacy with that of 2 other topical treatment protocols: a 25% podophyllin resin (P) and a 25% podophyllin resin with a 5% acyclovir cream (PA).
Study Design: Forty-two human immunodeficiency virus-positive patients with 69 OHL lesions were randomly treated using P, PA, or PP (14 patients in each topical treatment protocol). Clinical healing was determined when the white plaque could no longer be seen in the primary location of the lesion.
Article Synopsis
- A study was conducted to evaluate the prevalence of oral mucosal conditions among Brazilian patients with chronic hepatitis C, involving 215 participants.
- The results showed an extremely high prevalence (96.3%) of oral mucosal conditions, with 68.4% showing lesions and 80.5% showing variations of normality.
- The study highlighted a significant association between oral lichen planus and hepatitis C, emphasizing the importance of recognizing oral health issues for early diagnosis of HCV, especially in asymptomatic individuals.
Article Synopsis
- The article discusses the clinical characteristics and management of oral side effects caused by the antiretroviral drug Nevirapine (NVP), which is used to treat HIV infections.
- A case study of a 29-year-old HIV-infected man showed that after experiencing adverse effects like oral lesions and dry mouth from NVP, his symptoms completely resolved after stopping the medication.
- The study highlights the importance of recognizing these oral side effects in order to improve adherence to HIV treatments and calls for more research to understand these reactions better.
A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
January 2007
Objective: The objective of this study was to assess the efficiency of topical applications of podophyllin resin (25%) (P) versus podophyllin resin (25%) together with acyclovir cream (5%) (PA) in the treatment of oral hairy leukoplakia (OHL) in accordance with the following criteria: (1) number of applications necessary for the total clinical resolution of OHL; (2) correlation between the decrease of lesion size and the number of applications; (3) total clinical resolution of OHL; and (4) clinical reevaluation 12 months after the end of treatment.
Study Design: Forty-six OHLs were treated with P (P group) or with PA (PA group). Applications were performed weekly.
Background: Oral hairy leukoplakia (OHL) may be an indicator of the progression of Human Immunodeficiency Virus (HIV)-induced immuno-depression, and the evaluation of risk factors leading to OHL is important in the management of these HIV-infected patients. However, there are few studies that analyze risk factors leading to OHL in the Brazilian population. The aim of this case-control study is to present data about prevalence rates and risk factors leading to OHL in a sample of HIV-infected adults in Brazil.
View Article and Find Full Text PDFPurpose: We sought to evaluate the response of 6 patients with masseter muscle hypertrophy to botulinum toxin type A therapy.
Patients And Methods: Six patients with unilateral or bilateral masseter muscle hypertrophy received intramuscular injection of the botulinum toxin type A. The functional and cosmetic results were evaluated as well as recurrence.